1
|
Zhang L, Fu X, Gui T, Wang T, Wang Z, Kullak-Ublick GA, Gai Z. Effects of Farnesiferol B on Ischemia-Reperfusion-Induced Renal Damage, Inflammation, and NF-κB Signaling. Int J Mol Sci 2019; 20:ijms20246280. [PMID: 31842453 PMCID: PMC6940812 DOI: 10.3390/ijms20246280] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Revised: 12/03/2019] [Accepted: 12/10/2019] [Indexed: 12/26/2022] Open
Abstract
Background: G-protein-coupled bile acid receptor (TGR5), a membrane bile acid receptor, regulates macrophage reactivity, and attenuates inflammation in different disease models. However, the regulatory effects of TGR5 in ischemia/reperfusion (I/R)-induced kidney injury and inflammation have not yet been extensively studied. Therefore, we hypothesize that Farnesiferol B, a natural TGR5 agonist, could alleviate renal I/R injury by reducing inflammation and macrophage migration through activating TGR5. Methods: Mice were treated with Farnesiferol B before I/R or sham procedures. Renal function, pathological analysis, and inflammatory mediators were examined. In vitro, the regulatory effects of Farnesiferol B on the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway in macrophages were investigated. Results: After I/R, Farnesiferol B-treated mice displayed better renal function and less tubular damage. Farnesiferol B reduced renal oxidative stress and inflammation significantly. In vitro, Farnesiferol B treatment alleviated lipopolysaccharide (LPS)-induced macrophage migration and activation, as well as LPS-induced NF-κB activation through TGR5. Conclusions: Farnesiferol B could protect kidney function from I/R-induced damage by attenuating inflammation though activating TGR5 in macrophages. Farnesiferol B might be a potent TGR5 ligand for the treatment of I/R-induced renal inflammation.
Collapse
Affiliation(s)
- Lu Zhang
- College of Traditional Chinese Medicine; Shandong Co-innovation Center of TCM Formula; Institute for Literature and Culture of Chinese Medicine; Key Laboratory of Traditional Chinese Medicine for Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
- Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, 8006 Zurich, Switzerland
| | - Xianjun Fu
- College of Traditional Chinese Medicine; Shandong Co-innovation Center of TCM Formula; Institute for Literature and Culture of Chinese Medicine; Key Laboratory of Traditional Chinese Medicine for Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
| | - Ting Gui
- College of Traditional Chinese Medicine; Shandong Co-innovation Center of TCM Formula; Institute for Literature and Culture of Chinese Medicine; Key Laboratory of Traditional Chinese Medicine for Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
| | - Tianqi Wang
- College of Traditional Chinese Medicine; Shandong Co-innovation Center of TCM Formula; Institute for Literature and Culture of Chinese Medicine; Key Laboratory of Traditional Chinese Medicine for Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
| | - Zhenguo Wang
- College of Traditional Chinese Medicine; Shandong Co-innovation Center of TCM Formula; Institute for Literature and Culture of Chinese Medicine; Key Laboratory of Traditional Chinese Medicine for Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
| | - Gerd A. Kullak-Ublick
- Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, 8006 Zurich, Switzerland
- Mechanistic Safety, CMO & Patient Safety, Global Drug Development, Novartis Pharma, 4056 Basel, Switzerland
- Correspondence: (G.A.K.-U.); (Z.G.); Tel.: +43-253-31-45
| | - Zhibo Gai
- College of Traditional Chinese Medicine; Shandong Co-innovation Center of TCM Formula; Institute for Literature and Culture of Chinese Medicine; Key Laboratory of Traditional Chinese Medicine for Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
- Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, 8006 Zurich, Switzerland
- Correspondence: (G.A.K.-U.); (Z.G.); Tel.: +43-253-31-45
| |
Collapse
|